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INTRODUCTION
Incorporating genome sequencing into the research environ-
ment and clinical care requires a better understanding of the 
risks and benefits in different clinical contexts, including pre-
conception carrier screening. The purpose of preconception 
carrier screening is to provide information to families to assist 
with reproductive decision-making, including options for pre-
natal and pre-implantation genetic diagnosis and options for 
using donor gametes and adoption to reduce the likelihood 
of having a child with a genetic condition, or to assist with 
decisions about whether to have children. Preconception car-
rier screening could also help mitigate the impact of a disor-
der through earlier diagnosis and treatment. However, as with 
other novel genetic testing strategies, the technical ability to 
perform laboratory analyses has occurred at a faster rate than 
the evidence base for optimal integration of this information 
into health-care delivery.
In 2011, the National Human Genome Research Institute and 
the National Cancer Institute initiated the Clinical Sequencing 
Exploratory Research (CSER) consortium1 to support multidi-
mensional research regarding the optimal uses and implemen-
tation of whole-genome and whole-exome sequencing. CSER is 
a national interdisciplinary consortium of projects for develop-
ing and sharing innovations and best practices for the integra-
tion of genomic sequencing into clinical care. As a part of the 
CSER consortium, the NextGen study has been investigating 
the use of genome sequencing for preconception carrier testing.
In current clinical practice, some extremely rare genetic 
conditions are tested with large (~100 conditions) carrier test-
ing panels. Although it is possible for a patient to review ~100 
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Purpose: We investigated the use of genome sequencing for pre-
conception carrier testing. Genome sequencing could identify one 
or more of thousands of X-linked or autosomal recessive condi-
tions that could be disclosed during preconception or prenatal 
counseling. Therefore, a framework that helps both clinicians and 
patients understand the possible range of findings is needed to 
respect patient preferences by ensuring that information about 
only the desired types of genetic conditions are provided to a 
given patient.
Methods: We categorized gene–condition pairs into groups using a 
previously developed taxonomy of genetic conditions. Patients could 
elect to receive results from these categories. A Return of Results 
Committee (RORC) developed inclusion and exclusion criteria for 
each category.
Results: To date, the RORC has categorized 728 gene–condition 
pairs: 177 are categorized as life span–limiting, 406 are categorized as 
serious, 93 are categorized as mild, 41 are categorized as unpredict-
able, and 11 are categorized as adult-onset. An additional 64 gene–
condition pairs were excluded from reporting to patients or put on a 
watch list, generally because evidence that a gene and condition were 
associated was limited.
Conclusion: Categorization of gene–condition pairs using our tax-
onomy simplifies communication regarding patient preferences for 
carrier information from a genomic test.
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conditions from current carrier panel screening, there are 
nearly 3,0002 X-linked and autosomal recessive conditions that 
could potentially be disclosed during preconception or prenatal 
counseling. A framework that helps both clinicians and future 
patients seeking preconception carrier screening to understand 
the possible range of findings is needed. Interestingly, there is 
little research on the types of carrier information that couples 
are interested in learning about, the psychological implications 
for couples at risk for having a child with these conditions, 
and the practical demands on the health-care delivery system. 
Expanding the scope of results from current carrier panels to 
genome-scale sequencing will provide further information for 
reproductive planning, but it excludes the possibility of a mean-
ingful discussion of each gene–condition pair being evaluated.
By grouping disorders into categories,3 we developed a tax-
onomy framework that enables patients to decide what infor-
mation they want. As part of the development of the taxonomy, 
we obtained feedback on initial drafts of the taxonomy from 
women in focus groups who previously underwent carrier 
testing for reproductive decision making. A key recommenda-
tion strongly expressed by all participants was the importance 
of providing choice at every level of offering genomic carrier 
screening—including the type and quantity of results being 
shared. They also supported assumptions that disease severity 
and age at onset are important factors, and that “shortened life 
span” is a discrete category of its own. Variability of a disor-
der was a less critical criterion for categorization and, in the 
case of a range of phenotypes, the most severe should be used.4 
This focus group feedback, in conjunction with edits from the 
NextGen study personnel, led to final taxonomy categories 
of lifespan limiting, serious, mild, unpredictable, and adult-
onset.3,5 This taxonomy was validated in another population of 
reproductive-age women who had carrier testing performed.4
The concept of “binning” genetic conditions was proposed 
by Berg et al.6 and was first described for incidental findings 
for patients who undergo genome or exome sequencing. By 
selecting disclosure of information relevant to patients, a cat-
egory-based approach facilitates informed consent and patient 
education and support. We adapted this approach to precon-
ception carrier testing3,5 and have categorized relevant gene–
disorder pairs with this taxonomy.
Here, we describe the experience of the CSER/NextGen study 
regarding: (i) deciding which gene–condition pairs will be dis-
closed for preconception carrier screening and (ii) categorizing 
the gene–condition pairs into our taxonomy of genetic condi-
tions. We present the categories in which the gene–condition 
pairs were placed. In addition, we discuss the challenges and 
lessons learned during this process.
MATERIALS AND METHODS
We convened a panel of experts, called the Return of Results 
Committee (the RORC), to determine reportable results for 
carrier screening from a genome-scale test. The RORC com-
prises a diverse group of experts in genetics and public health, 
including medical geneticists with metabolic, pediatric, and 
internal medicine expertise; genetic counselors; molecular 
laboratory directors and PhD geneticists; a perinatologist; a 
medical ethicist; and a genetic epidemiologist. The committee 
is chaired by a board-certified medical geneticist. The specific 
tasks of the RORC included:
1. Creating a list of gene–condition pairs for consideration 
of disclosure of carrier status
2. Determining which gene–condition pairs should be dis-
closed to participants
3. Categorizing the gene–condition pairs into a previously 
established taxonomy of genetic conditions: lifespan lim-
iting, serious, mild, unpredictable, and adult-onset.
Sources of gene–condition pairs
The initial list of candidate genes associated with autoso-
mal recessive and X-linked conditions included those genes 
for which national professional organizations, including the 
American College of Medical Genetics and Genomics and the 
American Congress of Obstetricians and Gynecologists, rec-
ommended screening in at least one population, genes pres-
ent on carrier tests from commercial laboratories that offered 
expanded carrier testing in 2013, genes associated with con-
ditions that are commonly found on newborn screening pan-
els, and genes associated with serious childhood recessive 
diseases.7 The list was then augmented by nominations from 
RORC members, such as genes associated with conditions with 
X-linked inheritance, genes associated with the most common 
indications for referral to a clinical genetics department, mito-
chondrial genes (to ensure consideration of conditions with 
unpredictable outcome), and other genes associated with phe-
notypes already included on the list, such as genes associated 
with Leigh syndrome, sensory neural hearing loss, retinitis pig-
mentosa, and Usher syndrome.
Development and application of inclusion and exclusion 
criteria for gene–condition pairs to be offered to 
participants
Using published recommendations by professional organiza-
tions as a guide,8–15 the RORC developed criteria for decid-
ing whether to disclose to patients certain results from carrier 
screening. These criteria emphasize return of clinically valid 
gene–disease-associated pairs (Table 1). So that CSER/NextGen 
would be able to better understand the benefits and risks of 
using genome sequencing for preconception carrier screening 
for patients, health-care providers, and health-care systems, we 
were intentionally broadly inclusive of the gene–condition pairs 
to be offered to participants within this framework.
The RORC reviewed the nominated genes to decide which 
gene–condition pairs met the proposed criteria. Each gene–
condition pair was initially reviewed by one of the study 
genetic counselors, who summarized the available evidence 
(including the clinical characteristics, associated mortality, and 
genotype–phenotype correlation). Given the large number of 
 Volume 19  |  Number 7  |  July 2017  |  Genetics in meDicine804
Disclosure and categorization of carrier findings from genome sequencing  |  HIMES et al Original research article
gene–condition pairs, the literature review was frequently lim-
ited by time constraints; sometimes committee members with 
particular expertise on a specific condition would conduct this 
preliminary review. In addition, outside experts in specific 
fields, especially metabolic disorders, were consulted. The evi-
dence for each gene–condition pair was individually reviewed 
by each RORC member and augmented by the clinical expe-
rience of committee members. Unanimous agreement was 
required for a gene–condition pair to be included on the list.
Each gene–condition pair was assigned to an included, 
excluded, or watch category. Gene–condition pairs were 
excluded from the list when there was insufficient current evi-
dence that variants in that gene are associated with disease. 
Pairs were excluded because of limited evidence, including dis-
ease association only from genome-wide association studies, 
isolated case reports in the literature, and genes identified in 
only a single family. Many excluded gene–condition pairs were 
placed on a watch list awaiting future data. Conditions asso-
ciated with dominant inheritance were excluded except when 
homozygosity or compound heterozygosity was also known 
to be associated with a condition of interest, such as BRCA2 
pathogenic variants and Fanconi anemia D1. New information 
will likely arise during the course of the CSER/NextGen study 
and alter the assignments to the included, excluded, and watch 
categories.
Categorization of gene–condition pairs into taxonomy
Our team previously reported the development and validation 
of a taxonomy of conditions for reporting carrier status: lifes-
pan limiting, serious, mild, unpredictable, and adult-onset.4,5 
Operational definitions for these categories are briefly summa-
rized in Table 2. Evidence about each gene–condition pair was 
summarized by a member of RORC, who provided a prelimi-
nary assignment. After review of the summary description and 
based on the experience of RORC members, the final category 
was decided by the RORC. Because preconception identifica-
tion implies that knowledge of the condition would be known 
prior to birth, we approached categorization from the premise 
that treatment would begin promptly for treatable conditions. 
As noted in Table 2, if treatment is not highly burdensome 
(e.g., X-linked ichthyosis), then a condition would be consid-
ered mild. If treatment is available but is still a major burden 
to families and the proband (e.g., phenylketonuria), then that 
condition would still be in the serious category.
Each condition was placed in only one category unless there 
were recognizable genotype–phenotype associations that could 
be distinguished based on genotype (i.e., different genes or 
different pathogenic variants in the same gene causing a dif-
ferent phenotype). In this case, each distinguishable form was 
placed in a separate category. For example, a common pro-
motor region variant in the UGT1A1 gene is associated with 
Gilbert syndrome, which is typically characterized by benign 
Table 1 Criteria for disclosing results for carrier screening
•  Include genes associated with recessive or X-linked genetic disorders:
    o  When prenatal carrier screening is offered or
    o  That meet one or more of the following criteria in many people with a disorder that:
      ■  Limits the lifespan
      ■  Requires significant medical involvement and/or medical care cost
      ■  Causes significant physical, cognitive, or sensory impairment
      ■  Demands significant daily care and/or care cost to the family
      ■  Is risky for the mother during pregnancy
      ■  Can be treated to significantly mitigate or reverse symptoms
•   Include genes associated with disorders that meet the aforementioned criteria for only some people with the disorder because of variable expressivity, 
incomplete penetrance, or mild phenotype. Results for these genes will be clearly identified.
•  Exclude genes when there is insufficient evidence of pathogenicity.
•  Exclude genes in which variants are associated with risk for disease.
•   Exclude conditions associated with dominant inheritance except when homozygosity or compound heterozygosity is known to be associated with a 
specific phenotype.
Table 2 Taxonomy of conditions
Lifespan limiting (childhood):  More than 50%a of patients die before age 10 and most die before age 30.
Serious:   Default category. A condition was placed in this category unless it appeared to have a better fit in one of the other categories. If there is 
variation in phenotype, then the majority of patients (>50% a) have the most severe form.
Mild:   Signs and symptoms of the condition are not typically life-threatening. Patients usually experience mild or moderate disruption to normal activities 
and functions (e.g., poor vision vs. blindness). If available, the treatment itself is not highly burdensome in terms of medical interventions or lifestyle 
modifications that are required. With treatment, patients may experience few or no symptoms.
Unpredictable:   There is a wide range in the severity of the phenotype. Age at onset, severity of symptoms, or presence of symptoms may vary. The 
severity of the condition is unknown for a particular individual based on genotype. Fewer than half of patients have the most severe form.
Adult-onset:   For approximately 75% a of patients, symptoms do not appear until after age 20.
aSpecific percentages listed are meant as clarifiers to the descriptive words rather than thresholds. In many instances, the chances of certain events happening have not been 
precisely reported.
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hyperbilirubinemia; therefore, the UGT1A1–Gilbert syndrome 
pair was classified as mild. However, missense variants in this 
gene can be associated with Crigler-Najjar syndrome, which is 
characterized by hypotonia, intellectual disability, and death in 
childhood; therefore, the UGT1A1–Crigler-Najjar syndrome 
pair was classified as serious.
RESULTS
The RORC categorized a list of 728 gene–condition pairs (Table 
3). A total of 177 were categorized as lifespan limiting, 406 were 
categorized as serious, 93 were categorized as mild, 41 were 
categorized as unpredictable, and 11 were categorized as adult-
onset. In addition, 64 gene–condition pairs were excluded or 
put on a watch list (Supplementary Tables S1–S6 online).
Challenges faced by the Return of Results Committee
Determining suitable categorizations for rare conditions with 
a limited number of case reports presented the greatest chal-
lenge for the RORC. Published literature often provided insuf-
ficient information on survival and the possible variability in 
expression in rare genetic conditions. In addition, the com-
mittee suspected that cases reported in the medical literature 
are biased toward more severe presentations; therefore, it was 
difficult to find data to accurately categorize such conditions 
as lifespan limiting or unpredictable. In this context, condi-
tions were typically placed in the default category of serious. 
We anticipate that categorization of gene–condition pairs will 
evolve as additional information regarding clinical presentation 
becomes available and more cases that represent the mild end 
of the spectrum are observed. This assumption will need to be 
investigated in a population of ethnically diverse couples dur-
ing both the preconception and prenatal time period.
Genes associated with a spectrum of clinical presentations 
have presented challenges, especially when there are no known 
genotype/phenotype correlations and phenotypic variability is 
reported within the same family. For example, pathogenic vari-
ants in the CEP290 gene have been found in individuals with 
Leber congenital amaurosis (associated with isolated vision 
loss) and in people with Meckel syndrome (usually a life span–
limiting condition associated with encephalocele and cystic 
dysplastic kidneys). In such cases, the committee ultimately 
elected to categorize the gene–condition pair in the lifespan 
limiting category because we expect that patients will be more 
likely to want results from the more severe end of the spectrum.
DISCUSSION
We identified specific criteria for selecting gene–condition pairs 
for disclosing carrier status, developed operational definitions 
for these criteria, and, to date, applied the criteria of 792 gene–
condition pairs to consideration by the RORC. By unanimous 
agreement of the committee, we identified 728 gene–condition 
pairs that met these criteria and 64 gene–condition pairs that 
did not. These findings may be useful to others interested in 
disclosing carrier status from genome or exome sequencing.
We modeled our approach on practices that have been devel-
oped elsewhere. Berg et al.16 described the procedures developed 
by six sites in the CSER consortium, including committees with 
expertise similar to our own. Most sites established an a priori 
list to decide which gene–condition pairs would be disclosed. 
Professional organizations and recommendations from other 
sources8,17,18 suggest that decisions regarding what to disclose 
for carrier status should be based on set criteria rather than the 
inclusion of as many gene–condition pairs as possible. We have 
articulated clear criteria and operational definitions for making 
decisions about results disclosure.
The strength of our approach is that it enables patients to 
decide what kinds of results to receive from genome or exome 
sequencing without having to review all gene–condition pairs 
for which carrier status may be identified. The concepts of “bin-
ning” results and allowing participants to choose what kinds of 
results to receive from genome or exome sequencing are consis-
tent with general practice. As Berg et al.6 noted, a binning sys-
tem is scalable and directly involves a patient-driven approach 
to results disclosure by allowing individuals to opt in or out of 
certain categories (“bins”) according to their preference.
There were multiple limitations to our approach. We did not 
include all possible recessive or X-linked conditions to make 
the process feasible, and we excluded gene–condition pairs with 
limited causal evidence. Some categorizations may change as 
more information accumulates, particularly for very rare con-
ditions. In addition, we did not incorporate patient groups or 
the public in the process of classifying gene–condition pairs. 
Although patients were involved in the creation of the initial 
taxonomy,4,19 they were not involved in the RORC. It is pos-
sible that they may have had a different perspective when clas-
sifying some of the conditions, especially if they had personal 
experience with a condition. Finally, our criteria did not con-
sider whether it is technically feasible to report findings for 
a particular gene by using a particular sequencing platform. 
For instance, the platform we use has low coverage for SMN1; 
therefore, we do not report findings for this gene, even though 
it is included in the category of lifespan limiting.
Our RORC and others continue to systematically collect 
information regarding participants’ preferences about the 
types of results that patients want disclosed by giving them 
choices.4,5,16 In our own work validating the taxonomy with 
patients’ perspectives, it is challenging to distinguish between 
Table 3 Example conditions by category (N = 728)
Category n Examples
Lifespan limiting 177 Krabbe disease (GALC), Tay–Sachs disease 
(HEXA)
Serious 406 Duchenne muscular dystrophy (DMD), 
Cystic fibrosis (CFTR)
Mild 93 Cystinuria type A (SLC7A9),  
hereditary fructose intolerance (ALDOB)
Unpredictable 41 Gaucher disease (GBA),  
Schindler disease I (NAGA)
Adult-onset 11 Hemochromatosis (HFE),  
Alpha1 antitrypsin deficiency (SERPINA1)
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the serious and mild categories because of the subjective nature 
of how serious a condition is. The operational definitions of the 
categories were created and validated based on the results of a 
survey with reproductive-age women who had undergone prior 
carrier testing.4,5 In discussions, the RORC itself frequently had 
a difficult time distinguishing between these categories. Wertz 
and Knoppers (2002)20 also previously discussed the inconsis-
tency in how genetics professionals define the “seriousness” of 
conditions. In the future, we may collapse these categories. As 
other genetic factors that modulate the clinical presentation of 
“single-gene” disorders are identified, the process of categoriz-
ing conditions will become even more complicated.
Although the RORC members had a broad range of exper-
tise and perspectives, we often relied on individual experience 
with and knowledge about conditions. Also, although the time 
to review and classify conditions was substantial, it was never-
theless limited for any given condition. Moving beyond these 
limitations will require broader community engagement. The 
ClinGen Consortium is one example that includes mechanisms 
for engaging both experts (e.g., clinicians, laboratorians, and 
researchers) and individual patients, supporting broad data-
sharing, and assembling platforms for curating evidence.21 
Ultimately, a broad, community-based approach to categori-
zation of gene–condition pairs for disclosing carrier status is 
needed to enable individual organizations to leverage the efforts 
by others, limit redundancy, and produce greater consistency in 
interpretation.
Several professional organizations have proposed types of 
carrier results that could be considered for disclosure. Edwards 
et al.18 noted the importance of restricting carrier testing pan-
els to conditions associated with cognitive disability, the need 
for surgical or medical intervention, the effect on quality of life, 
and the prenatal diagnosis that would alter prenatal or post-
natal management. The American College of Medical Genetics 
and Genomics8 recommends restricting carrier testing to con-
ditions that would be considered for reproductive decision 
making. Our own list includes numerous conditions for which 
prenatal testing is rarely requested, including genes associated 
with adult-onset conditions, unpredictable outcomes, and con-
ditions such as hearing or vision loss that we included in our 
study to determine patient preferences. The National Society 
of Genetic Counselors22,23 articulated that prenatal testing for 
adult-onset disorders should be discouraged unless pregnancy 
management would be altered or clinical intervention would be 
initiated during childhood; this position reflects the desire to 
protect the autonomy of a future child.
RORC activities were conducted in the context of a research 
study, which differs from clinical care in both methods and 
goals. Therefore, the choices made for the purposes of the 
CSER/NextGen study should not be interpreted as recommen-
dations for clinical care.24 The list included genes associated 
with very rare conditions, for which the detection rate, car-
rier frequency, and breadth of clinical presentations are poorly 
understood. There is the possibility of increasing anxiety asso-
ciated with these sorts of results. An overarching purpose of 
the CSER/NextGen study was to explore the types of informa-
tion that could be disclosed to patients for carrier status or that 
might be desired by individuals. To assess individuals’ bound-
aries, we created a broad and inclusive scope for disclosure. 
As yet, there is no agreement in the patient or provider com-
munities regarding how or whether carrier screening should be 
expanded. However, Lazarin et al.25 recently conducted a sur-
vey with genetic counselors that indicated general agreement 
with expanded carrier screening: only 27% agreed that carrier 
screening should be limited to conditions recommended in 
current guidelines for general population screening and 80% 
of the respondents preferred to be tested for a larger number of 
disorders themselves if the financial costs were the same.25
We previously published a taxonomy for binning of carrier 
gene–condition pairs to be offered to patients wanting reports 
of genome-scale carrier status. Now, we have reported the cat-
egorization of such gene–condition pairs in our taxonomy. Our 
approach used a diverse array of methods and stakeholder opin-
ions to create an initial categorization schema for the return of 
genome-scale sequencing, including reviewing existing litera-
ture, obtaining expert opinion, and conducting patient surveys 
and focus groups. This method of classifying gene–condition 
pairs will allow patients to make choices within a simplified 
framework. Additional work is now needed to evaluate these 
categories in practice, allowing for refinement and adjustment 
as needed based on more patient and provider feedback. Future 
work can also seek to understand the benefits and risks from 
the individual and societal perspectives on disclosing carrier 
status beyond the current guidelines for sequencing.
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